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Background
Nitric oxide (NO) is considered to play a critical role in
the control of erectile function, by activating soluble gua-
nylyl cyclase (sGC) in cavernosal smooth muscle to gen-
erate cGMP, which, in turn, promotes relaxation leading
to penile erection. The pyrazolopyridine 5-cyclopropyl-2-
[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyri-
midin-4-ylamine (BAY 41–2272) sensitizes sGC to NO,
lowers mean arterial pressure in spontaneously hyperten-
sive rats and increases survival in a low-NO rat model of
hypertension. In vitro, BAY 41–2272 causes potent relax-
ation of vascular smooth muscle, rat anococcygeus muscle
as well as human and rabbit corpus cavernosum (CC).
Purpose
The aims of the present work were to characterize the
mechanisms involved in the relaxant responses induced
by BAY 41–2272 and the pharmacological interactions
between this compound and NO in the CC from wild-
type (WT), eNOS-/- and nNOS-/- mice. We also assessed
the effect of BAY 41–2272 on superoxide formation and
NADPH oxidase expression in cavernosal smooth muscle
treated with the thromboxane A2 mimetic U46619.
Methods
In functional studies, cavernosal strips were mounted
under a resting tension of 2 mN in a myograph for isomet-
ric force recording, coupled to a PowerLab 8/SP™ data
acquisition system. Cavernosal strips were stimulated for
10 min with BAY 41–2272 (1 μM), SNP (1 μM), or their
combination. Cyclic GMP was extracted and quantified
using commercially available kits. sGC activity in the pres-
ence of BAY 41–2272 was determined in the supernatant
fractions of the cavernosal samples by the conversion of
GTP to cGMP. Thirty μg of each sample was incubated for
10 min at 37°C in a total volume of 100 μl containing 50
mM Tris-HCl (pH 7.4), 1 mM 3-isobutyl-1-methylxan-
tine, 3 mM MgCl2, 0.5 mM GTP, 3 mM DTT, 5 mM phos-
phocreatine and 0.25 mg/ml creatine kinase. The reaction
was terminated by inactivation of sGC at 95°C for 10 min,
and cGMP measured. Segments of CC were incubated
with U46619 with or without BAY 41–2272 for 1 or 8 h at
37°C. Superoxide dismutase-inhibitable superoxide for-
mation was assessed using the reduction of ferricyto-
chrome c measured spectrophotometrically, and NADPH
oxidase subunits assessed using Western blot analysis.
Results
BAY 41–2272 (0.01–10 μM) relaxed CC with pEC50 values
of 6.36 ± 0.07, 6.27 ± 0.06 and 5.88 ± 0.07 in WT, nNOS-
/- and eNOS-/- mice, respectively (Fig. 1). L-NAME (100
μM) rightward shifted the curves to BAY 41–2272 by 3-
fold in CC from WT and nNOS-/-, but not eNOS-/-. ODQ
(10 μM) reduced BAY 41-2272-evoked relaxations as evi-
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from WT, nNOS-/- and eNOS-/- mice. Sildenafil (0.1 μM)
potentiated the relaxations induced by BAY 41–2272 in
all groups. BAY 41–2272 (0.01–0.1 μM) enhanced SNP-
induced CC relaxations in all groups in a concentration-
dependent manner. In addition, BAY 41–2272 potenti-
ated acetylcholine (ACh, 0.01–1 μM)- and electrical field
stimulation (EFS, 1–16 Hz)-induced relaxations. At 1 μM,
BAY 41–2272 caused a 30-fold increase in cGMP concen-
tration in WT and nNOS-/- samples versus an 18-fold
increase in eNOS-/- CC. Co-incubation with SNP (1 μM)
resulted in a synergistic increase in cGMP levels in an
ODQ-sensitive manner. Expression and activity of sGC
did not significantly differ in CC from WT, nNOS-/- and
eNOS-/-. Superoxide formation was significantly greater
in tissues incubated with U46619 after 1 and 8 h incuba-
tion than in controls, an effect blocked by NADPH oxi-
dase inhibitors. These effects of U46619 were inhibited by
BAY 41–2272 (0.01–0.1 μM), which in turn were negated
by the guanylyl cyclase inhibitor, ODQ (10 μM). BAY 41–
2272 also inhibited p22phox and gp91phox expression
induced by U46619.
(a) Concentration-response curves to BAY 41–2272 (0.01–10 μM) in CC from wild-type (WT), eNOS and nNOS knockout animals (n = 6); (b) Formation of cGMP under basal conditions and after stimulation by BAY 41–2272 (0.001–1 μM) in crude protein extrac s of caver osal tissue; (c) I hibitory effect of BAY 41–2272 (0.01–0.1 μM) on sup roxide formation elicited by incubatio  of CC with U46619 ver a 8 h periodFigure 1
(a) Concentration-response curves to BAY 41–2272 (0.01–10 μM) in CC from wild-type (WT), eNOS and nNOS knockout 
animals (n = 6); (b) Formation of cGMP under basal conditions and after stimulation by BAY 41–2272 (0.001–1 μM) in crude 
protein extracts of cavernosal tissue; (c) Inhibitory effect of BAY 41–2272 (0.01–0.1 μM) on superoxide formation elicited by 
incubation of CC with U46619 over a 8 h period.
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Our results demonstrated that BAY 41–2272 potently
relaxes the CC, synergistically with NO released from the
endothelium and/or nitrergic nerves. In addition, BAY
41–2272 is a potent inhibitor of superoxide formation in
the penis. This effect is mediated through the accumula-
tion of cGMP, which in turn inhibits NADPH oxidase
expression and activity. Therefore, sGC activation in the
penis by BAY 41–2272 directly or via enhancement of NO
effects may provide a novel treatment for erectile dysfunc-
tion, particularly in the event of an increased intrapenile
oxidative stress.Page 3 of 3
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